

Sanofi abandons two drugs after trial failures

June 3 2013

Drugmaker Sanofi is abandoning two drugs in the late stages of development after trials revealed they weren't more effective than other therapies.

One drug, iniparib, was given to [lung cancer patients](#) in combination with chemotherapy and compared to treatments of chemotherapy alone. The company said Monday iniparib did not improve the patients' survival rate.

Another, the blood thinner otamizaben, was tested against a combination of heparin and eptifibatide, both of which prevent blood clots. It did not prove more effective than those therapies.

The failures of these studies are a blow to Sanofi, which is struggling to develop [new drugs](#) after patents on several of its blockbuster drugs expired. It was especially hard hit the loss last year of the patent for Plavix, which was the world's second best-selling drug.

© 2013 The Associated Press. All rights reserved.

Citation: Sanofi abandons two drugs after trial failures (2013, June 3) retrieved 23 May 2024 from <https://medicalxpress.com/news/2013-06-sanofi-abandons-drugs-trial-failures.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--